The reduced expression of the CYP8B1 gene has been of interest for pharmacological therapies since, at an experimental level, the incidence of fatty liver, lowered cholesterol absorption, prevention of atherosclerosis, hypercholesterolemia, and formation of gallstones in diabetic mice, as well as glucose homeostasis, have been reduced [46,49]. This evidence concerns the gene CYP8B1 and gallstones.